Hepatitis B Treatment

First-Line Treatment Recommendation

For chronic hepatitis B, initiate treatment with entecavir 0.5 mg daily or tenofovir (disoproxil fumarate 300 mg or alafenamide 25 mg) daily, as these agents achieve >90% virologic suppression with minimal resistance and are the only recommended first-line options. 1, 2, 3

Treatment Indications: When to Start Therapy

HBeAg-Positive Chronic Hepatitis B

Treat when HBV DNA >20,000 IU/mL AND ALT >2× ULN 4, 1
Treatment can be delayed 3-6 months if spontaneous HBeAg seroconversion is anticipated, except in patients with apparent liver failure (jaundice, prolonged PT, hepatic encephalopathy, ascites) who require immediate treatment 4
For HBV DNA >20,000 IU/mL with ALT 1-2× ULN: observe or perform liver biopsy; treat if ALT subsequently rises or biopsy shows significant inflammation/fibrosis 4

HBeAg-Negative Chronic Hepatitis B

Treat when HBV DNA >2,000 IU/mL AND ALT >2× ULN 4, 1
For HBV DNA >2,000 IU/mL with ALT <2× ULN: observe or perform liver biopsy; treat if ALT rises or biopsy shows significant disease 4

Compensated Cirrhosis

Treat if HBV DNA ≥2,000 IU/mL, regardless of ALT level 4, 1
ALT should not be used as treatment criteria in cirrhosis because these patients already have significant fibrosis and frequently have near-normal ALT 4
Lifelong therapy is mandatory 4, 1

Decompensated Cirrhosis

Immediately treat all patients with any detectable HBV DNA, regardless of viral load level, HBeAg status, or ALT 1, 3
Peginterferon is absolutely contraindicated due to risk of further decompensation 3
Consider combination therapy with tenofovir plus lamivudine or entecavir monotherapy to minimize resistance risk 3

Immune Tolerant Phase

Antiviral therapy is not indicated for patients in immune tolerance phase 4
Exception: Consider treatment for immune tolerant patients who remain in this phase after age 40 or those with evidence of active/advanced liver disease on biopsy or non-invasive tests 4

Preferred First-Line Agents

Entecavir

Dose: 0.5 mg daily on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal) 5
Achieves 83% virologic suppression (HBV DNA <50 IU/mL) at 96 weeks 1, 3
No genotypic resistance detected after 8 years in treatment-naïve patients 1, 3

Tenofovir Disoproxil Fumarate (TDF)

Dose: 300 mg daily 1, 3
Achieves 93% virologic suppression at 48 weeks 1, 3
No resistance detected after 8 years 1, 3
Maintains efficacy even with baseline viral loads ≥9 log10 copies/mL 3

Tenofovir Alafenamide (TAF)

Dose: 25 mg daily 1, 3
Equally effective as TDF but with improved renal and bone safety profile 3
Preferred over TDF in patients at risk for renal dysfunction or metabolic bone disease 3

Peginterferon Alfa-2a

Alternative first-line option for finite treatment (48-52 weeks) 4
Higher rates of HBeAg and HBsAg loss compared to nucleos(t)ide analogues, particularly in genotype A infection 4
Contraindicated in decompensated cirrhosis 3
Requires subcutaneous injection and can be difficult to tolerate 4

Agents to Avoid as First-Line Therapy

Never use lamivudine, adefovir, telbivudine, or clevudine as first-line therapy due to low potency and/or high resistance rates 2, 3

Lamivudine: resistance rates reach 70% after 5 years 2, 3
Adefovir: inferior efficacy compared to tenofovir 3
Telbivudine: high resistance rates despite potent antiviral activity, plus risk of serious muscle-related complications 3

Treatment Duration

HBeAg-Positive Patients

Continue treatment for at least 1 year after HBeAg seroconversion, then an additional 3-6 months 1, 3
Exception: Patients with cirrhosis require lifelong therapy regardless of HBeAg seroconversion 4, 1

HBeAg-Negative Patients

Long-term or indefinite treatment is required, as relapse rates reach 80-90% if stopped within 1-2 years 1, 3

Cirrhotic Patients

Lifelong therapy is mandatory for all patients with decompensated cirrhosis 4, 1
Lifelong therapy is recommended for the majority of patients with compensated cirrhosis (F3-F4 fibrosis) 4

Monitoring During Treatment

Check HBV DNA and ALT levels at baseline and every 3-6 months during therapy 1, 3
Monitor HBeAg status regularly in HBeAg-positive patients 3
Monitor renal function, particularly with tenofovir DF 3
Consider monitoring bone density in patients on tenofovir DF with risk factors 3

Managing Inadequate Response

Partial Virologic Response

For patients on lamivudine or telbivudine: switch to tenofovir monotherapy 4, 1, 3
For patients on entecavir with partial response: add tenofovir or switch to tenofovir 3
First verify medication adherence, as this is the most common cause of breakthrough rather than true resistance 3

Virologic Breakthrough with Confirmed Resistance

Switch to tenofovir (DF or AF) or combine entecavir with tenofovir 1, 3
For lamivudine resistance: tenofovir monotherapy is sufficient 4
For adefovir resistance: switch to tenofovir monotherapy or tenofovir/entecavir combination 3
Patients with both rtA181T/V and rtN236T mutations may have inferior response to tenofovir monotherapy and require close monitoring 3

Special Populations

Lamivudine-Experienced Patients

Never use entecavir in patients with any prior lamivudine exposure, even if brief, due to risk of archived resistance mutations in HBV covalently closed circular DNA 1, 2, 3
Prefer tenofovir (DF or AF) in this population 3

HIV/HBV Co-infection

Tenofovir should be included in HAART regimen, combined with emtricitabine or lamivudine for simultaneous treatment of both viruses 4, 1
Entecavir is not recommended unless the patient is also receiving HAART 5
If entecavir is used without effective HIV treatment, it may increase the chance of HIV resistance to HIV medication 5
Patients should be offered HIV antibody testing before starting entecavir therapy 5

HDV Co-infection

Treat with peginterferon alfa for at least 1 year 4
Initiate nucleos(t)ide analogues for CHB if treatment indications are met or liver cirrhosis is present to prevent disease progression 4
Nucleos(t)ide analogues cannot inhibit HDV replication but are necessary to control HBV 4

Immunosuppression/Chemotherapy

All HBsAg-positive patients should receive prophylactic entecavir or tenofovir at the onset of chemotherapy or immunosuppressive therapy 1
HBsAg-negative/anti-HBc-positive patients receiving B cell-depleting agents or moderate-to-high dose corticosteroids require antiviral prophylaxis 2

Pregnancy

Peginterferon alfa is contraindicated during pregnancy and until 6 months after cessation 4
Nucleos(t)ide analogues may be used in the last trimester for women with high viremia to prevent vertical transmission 4
Tenofovir and lamivudine have the most reassuring safety data during pregnancy 4

Liver Transplant Recipients

Combination therapy with HBIG and lamivudine reduces HBV recurrence to <10% and is superior to high-dose HBIG monotherapy 4

Acute Hepatitis B

Oral antiviral therapy should be considered in cases of persistent serious hepatitis or acute liver failure 4
Treatment is generally not recommended for uncomplicated acute hepatitis B as >95% recover spontaneously 4

Critical Pitfalls to Avoid

Never use entecavir in patients with any prior lamivudine exposure, even if brief, due to risk of archived resistance mutations 1, 2, 3
Never discontinue therapy prematurely in HBeAg-negative patients or those with cirrhosis, as this can lead to severe hepatitis flares 1, 3
Never assume HBsAb confers immunity when HBsAg is also positive—this represents active infection requiring treatment 2
Never use combination therapy as initial treatment in treatment-naïve patients unless decompensated cirrhosis is present, as monotherapy with entecavir or tenofovir is equally effective 3
Never assume virologic breakthrough represents resistance without first confirming medication adherence 3
Never use peginterferon in patients with decompensated cirrhosis due to risk of further decompensation 3
Never use ALT as treatment criteria in cirrhotic patients, as they frequently have near-normal ALT despite significant disease 4

Post-Treatment Monitoring

Patients should be monitored closely for at least several months after discontinuation, as severe acute exacerbations can occur 5
Deterioration of liver disease may occur in some cases if treatment is discontinued 5
Hepatic function should be monitored with regular blood tests 5

Treatment Goals

The primary goal is sustained suppression of HBV DNA to undetectable levels to prevent progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma, and liver-related mortality 4, 1, 3

Secondary goals include ALT normalization and histologic improvement 3
The ideal endpoint is HBsAg loss with or without anti-HBs seroconversion 3
Treatment with entecavir does not cure HBV but may lower viral load, reduce ability of HBV to multiply and infect new liver cells, and improve liver condition 5
It is not known whether entecavir will reduce chances of getting liver cancer or cirrhosis 5

What is the recommended treatment for a patient with Hepatitis B (infectious liver disease caused by Hepatitis B virus)?

Help us tailor your experience